Addex Therapeutics Ltd
SIX:ADXN

Watchlist Manager
Addex Therapeutics Ltd Logo
Addex Therapeutics Ltd
SIX:ADXN
Watchlist
Price: 0.053 CHF -4.33%
Market Cap: 9.8m CHF

Addex Therapeutics Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Addex Therapeutics Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Addex Therapeutics Ltd
SIX:ADXN
Operating Income
-CHf2.1m
CAGR 3-Years
59%
CAGR 5-Years
37%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Operating Income
-$478.1m
CAGR 3-Years
11%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Operating Income
CHf76m
CAGR 3-Years
127%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
Operating Income
-CHf123.6m
CAGR 3-Years
47%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Operating Income
-CHf2.1m
CAGR 3-Years
40%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Relief Therapeutics Holding SA
SIX:RLF
Operating Income
-CHf19.6m
CAGR 3-Years
20%
CAGR 5-Years
-66%
CAGR 10-Years
N/A
No Stocks Found

Addex Therapeutics Ltd
Glance View

Market Cap
9.8m CHF
Industry
Biotechnology

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 28 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

ADXN Intrinsic Value
0.035 CHF
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Addex Therapeutics Ltd's Operating Income?
Operating Income
-2.1m CHF

Based on the financial report for Sep 30, 2025, Addex Therapeutics Ltd's Operating Income amounts to -2.1m CHF.

What is Addex Therapeutics Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
37%

Over the last year, the Operating Income growth was 58%. The average annual Operating Income growth rates for Addex Therapeutics Ltd have been 59% over the past three years , 37% over the past five years .

Back to Top